Bessemer Group Inc Catalyst Pharmaceuticals, Inc. Transaction History
Bessemer Group Inc
- $55.8 Billion
- Q1 2025
A detailed history of Bessemer Group Inc transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Bessemer Group Inc holds 533 shares of CPRX stock, worth $11,177. This represents 0.0% of its overall portfolio holdings.
Number of Shares
533
Previous 433
23.09%
Holding current value
$11,177
Previous $9,000
44.44%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CPRX
# of Institutions
383Shares Held
99.5MCall Options Held
37KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$392 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.5MShares$178 Million0.0% of portfolio
-
State Street Corp Boston, MA5.53MShares$116 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.42MShares$71.8 Million2.1% of portfolio
-
Goldman Sachs Group Inc New York, NY3.14MShares$65.8 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.16B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...